A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer

The aromatase inhibitors exemestane and anastrozole are approved in Japan for first-line treatment of postmenopausal patients with advanced, hormone-receptor-positive breast cancer. This phase 3, randomized, double-blind study directly compared time to progression (TTP) for exemestane and anastrozol...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Iwata, Hiroji, Masuda, Norikazu, Ohno, Shinji, Rai, Yoshiaki, Sato, Yasuyuki, Ohsumi, Shozo, Hashigaki, Satoshi, Nishizawa, Yoshinori, Hiraoka, Masahiro, Morimoto, Tadaoki, Sasano, Hironobu, Saeki, Toshiaki, Noguchi, Shinzaburo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer US 2013
Konular:
Clinical Trial
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3669502/
https://ncbi.nlm.nih.gov/pubmed/23715630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2573-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller